Chiesi Farmaceutici has a system of pharmacovigilance in order to assume liability for our medicinal products (whether marketed or under clinical development) and to take appropriate actions when necessary. We ensure that all information relevant to the benefit-risk ratio of our medicinal products is continuously evaluated. When important safety issues arise, if applicable, we promptly notify healthcare the professionals, patients and regulatory agencies concerned in accordance with current legislation.
Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem (Ref. World Health Organization, WHO. The importance of pharmacovigilance: safety monitoring of medicinal products, Genève, WHO, 2002).
In line with this general definition, the main objectives of pharmacovigilance in accordance with the applicable EU legislation are:
Pharmacovigilance is therefore an activity contributing to the protection of patient and public health.
A response to a medicinal product which is harmful and unintended (response in this context means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility).
Adverse reactions may arise from use of the product within or outside the terms of the marketing authorisation or from occupational exposure. Conditions of use outside the marketing authorisation include off-label use, overdose, misuse, abuse and medication errors.
Any untoward event that occurs following medical treatment must be promptly reported either to the family doctor or to the pharmacist.
If you need to report an adverse drug reaction related to Chiesi drugs, we kindly request that you follow the instructions indicated in the link below instead of using the website or email:
If you need to contact the Chiesi pharmacovigilance department directly you can:
call +386 (0)1 43 00 901
send an e-mail to: email@example.com
Every country has laws governing the reporting of adverse drug reactions, therefore if you experience adverse drug reactions with our medicinal products, you are asked to contact local health personnel to rightly follow the notification procedure.